Meeting of a scientific and business consortium under the NoteSzHD project

On 14 March this year another working meeting was held for the research project: "New treatment for psychotic disorders and Huntington's disease with special focus on cognitive deficits"  NoteSzHD, with Celon Pharma S.A. as the leader.

The meeting was participated in by representatives of the Nencki Institute of Experimental Biology of the Polish Academy of Sciences, the Mossakowski Medical Research Centre of the Polish Academy of Sciences, the Institute of Pharmacology of the Polish Academy of Sciences, the Medical University of Lodz and the Poznan University of Medical Sciences.

Mikołaj Matłoka, leader of the Research Group for Neurological and Metabolic Diseases at Celon Pharma S.A.:- The objective of the project is to develop an innovative therapy of psychotic disorders and Huntington's disease based on phosphodiesterase 10A inhibitors. The meeting focused on a presentation of results obtained in preclinical studies, their analysis with regard to toxicological tests for clinical candidates, which are to commence in the third quarter of this year, and an overview of the following key steps of the NoteSzHD project.

Scientific units along with Celon Pharma S.A. form a business-scientific consortium of the NoteSzHD project, where Celon Pharma is responsible for key activities associated with the development of the drug while the tasks of the remaining consortium members consist in exploration of mechanisms of action of phosphodiesterase 10A inhibitors (PDE10A).

The NoteSzHD project is co-financed from the National Centre for Research and Development in the amount of PLN 26,730,836 under the STRATEGMED programme.